Drug Trial Radar · NCT01406444
IGF-1 and Bone Loss in Women With Anorexia Nervosa
Last checked: Nov 20, 2026Latest source record: Jul 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Oct 2011
Primary completion
May 2019
Study completion May 2019
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 1, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. Women who have this condition often have thin or weak bones that are more likely to break. They also have very low levels of a chemical called IGF-1 in their body. This chemical is very important for increasing bone growth in puberty and for maintaining healthy adult bones. The investigators would like to find out if giving rhIGF-1 followed by risedronate or risedronate alone can lead to an increase in bone formation, bone density, and bone strength in women with anorexia nervosa.
Conditions
- Anorexia Nervosa
- Osteopenia
- Osteoporosis
Interventions
rhIGF-1Drug
Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
RisedronateDrug
Risedronate 35mg PO one time weekly
PlaceboDrug
Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postero-anterior Spine Bone Mineral Density by DXATime frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.